رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT07498400 لـ Breast Cancer (Triple Negative Breast Cancer (TNBC))، سرطان الثدي هي نشط (لا يقبل مشاركين جدد). اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer ٢١٦ عشوائية البقاء الكلي
The traditional ...
عرض المزيدA Multicenter, Randomized Controlled Study on the Exemption of Sentinel Lymph Node Biopsy After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer
- XJLL-KY-20262002
| مجموعة المشاركين/الذراع | التدخل/العلاج |
|---|---|
تجريبيةExemption of SLNB | Exemption of SLNB Breast-conserving surgery (or mastectomy) without sentinel lymph node biopsy (SLNB). Postoperatively, conventional radiotherapy (for breast-conserving therapy), endocrine (HR+) immunotherapy (for triple-negative cases), or HER2-targeted (HER2+) treatment is received. |
بدون تدخلNot Exemption of SLNB | غ/م |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Efficacy Measurement | 3-year AR (axillary recurrence rate): Axillary lymph node metastasis (stage I - III) confirmed by imaging (US/MRI/CT) or pathology within 3 years after surgery; not included in distant metastasis | 3 years |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
DFS | The time from the subject's enrollment to the first occurrence of a recurrent disease. Recurrent diseases include recurrence on the same side or on the opposite side of the breast, local or regional recurrence, distant recurrence, and any death caused by | 3 years |
OS | The time from enrollment to death due to any cause. | 3 years |
Complications | Surgery-related complications (lymphedema, pain, limited shoulder function) | 3 years |
QLQ C30 | Changes in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C30). The assessment form consists of 30 items. Each item is scored from 1 to 4 points. The higher the score, the more severe the symptoms and the poorer the quality of life. | 3 years |
ICER | Cost-effectiveness (ICER) | 3 years |
- Female, aged 18 to 70 years;
- Histologically diagnosed with invasive breast cancer, clinical stage T1-T2 (tumor maximum diameter ≤ 5 cm), clinical assessment as cN0 (physical examination + at least two negative imaging tests, including axillary ultrasound, and MRI or PET CT when necessary);
- Immunohistochemistry or ISH confirmed as HER2 positive (IHC 3+ or ISH positive) or triple-negative (ER, PR, HER2);
- Completed a standardized neoadjuvant chemotherapy regimen (including HER2-targeted or immune checkpoint inhibitors), and was assessed as clinical complete response (CCR) before surgery;
- No residual masses on physical examination;
- Imaging (MMG/US/MRI) shows the tumor ≤ 2 cm or complete disappearance;
- Preoperative or intraoperative biopsy (when necessary) confirmed no residual invasive cancer.
- ECOG 0-1, and expected to be able to receive whole breast radiotherapy after breast-conserving surgery.
- Voluntarily signed a written informed consent.
Tumor-related symptoms and treatment 1) Patients with metastatic breast cancer or bilateral breast cancer; 2) Patients with inflammatory breast cancer; 3) Patients with multiple lesion sites;
Comorbid diseases/medical history 1) Previously had other malignant tumors and received any systemic anti-tumor treatment or local treatment (including surgery and radiotherapy), excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma and other malignant tumors; 2) Within 4 weeks before enrollment, had undergone major surgeries unrelated to breast cancer or the patient had not fully recovered from such surgeries (biopsy for diagnostic purposes and peripheral venous puncture for central venous catheter insertion \[PICC\] are allowed); 3) Human immunodeficiency virus (HIV) infection or known acquired immune deficiency syndrome (AIDS); active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU/ml; hepatitis C, positive hepatitis C antibody and HCV-RNA above the detection limit of the analytical method) or co-infection with hepatitis B and hepatitis C; autoimmune hepatitis; 4) Previously or preparing to undergo allogeneic bone marrow transplantation or solid organ transplantation; 6) Severe heart disease or discomfort, including but not limited to the following diseases:
- History of diagnosed heart failure or systolic dysfunction (LVEF < 50%)
- High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia) or higher-level atrioventricular conduction block (i.e. Mobitz II second-degree atrioventricular conduction block or third-degree atrioventricular conduction block)
- Angina pectoris requiring anti-anginal drug treatment
- Clinically significant heart valve disease
- ECG showing transmural myocardial infarction
- Poorly controlled hypertension (systolic pressure > 180 mmHg and/or diastolic pressure > 100 mmHg)
Pregnant or lactating female patients, female patients with reproductive capacity and positive baseline pregnancy test results or fertile women patients who are unwilling to take effective contraceptive measures throughout the trial period.
Previously had a clear history of neurological or mental disorders, including epilepsy or dementia, and the subjects were known to have a history of substance abuse of psychotropic drugs, alcoholism or drug abuse; Other conditions that the investigator considers make the patient unsuitable to participate in this study.
Xijing Hospital